300404 Boji Medical Technology
- 9.46
- -0.03-0.32%
Boji Medical Technology News
Boji Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining an Invention Patent Certificate
Boji Pharmaceutical: Announcement on the company being recognized as a national specialized, special and new “little giant” enterprise
Broge Pharmaceuticals: Announcement on the abolition of some restricted stocks
Boji Pharmaceuticals: Announcement on Accruing Asset Impairment Losses, Credit Impairment Losses, and Asset Write-off
Boji Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining an Invention Patent Certificate
Boji Pharmaceutical: Legal Opinion of Beijing Kangda (Guangzhou) Law Firm on the Company\'s 2024 Second Shareholders\' Meeting
Boji Pharmaceutical: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Boji Pharmaceutical: Announcement on the completion of private equity fund filing by Boqi Investment Fund
Boji Pharmaceutical: Notice on increasing the number of insured persons within the guarantee amount of the company\'s business contract
Boji Pharmaceuticals: Announcement on Accruing Asset Impairment Losses, Credit Impairment Losses, and Asset Write-off
Boji Pharmaceutical: Notice on Using Temporarily Idle Own Funds for Cash Management
Broge Pharmaceuticals: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Boji Pharmaceutical: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Boji Pharmaceutical: Voluntary Disclosure Notice Regarding the Company\'s Signing of the “Strategic Cooperation Agreement”
Boji Medical Technology: Announcement Regarding Subsidiary Receiving Approval Notice for Clinical Trials of Drugs
Boji Medical Technology: Announcement on the participation of wholly-owned subsidiaries in investing in Dao Yuan Angel Private Equity Fund.
Boji Medical Technology: Announcement regarding the subsidiary's approval of the marketing authorization application for chemical raw material active pharmaceutical ingredient.
Boji Medical Technology: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Boji Medical Technology: Legal Opinion of Beijing Kangda (Guangzhou) Law Firm on the Company's 2023 Annual General Meeting of Shareholders
Boji Pharmaceutical: Notice on requesting the shareholders' meeting to authorize the board of directors to handle matters relating to small amount of rapid financing
Analysis
Price Target
No Data
No Data